Key Takeaways BMY's Sotyktu met primary and multiple secondary endpoints in a phase III PsA study. Sotyktu showed superior efficacy over placebo at Week 16 and sustained responses through Week 52. RayzeBio inked a $1.35B licensing deal for Philochem's prostate cancer therapy, OncoACP3.Bristol Myers (BMY) announced that the late-stage study on Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA) met its primary endpoint.Sotyktu is an oral, selective tyrosine kinase 2 (TYK2) inhibitor w ...

Writing under the pseudonym "out of ignorance", I very much regard investing as a learning process. Investing failures are tuition paid. Investing successes enter the trove of lessons learned. In my Seeking Alpha articles I share my experience from decades of investing and from ~5 years of focused research on a variety of stocks, in recent years with a primary emphasis on healthcare stocks. I greatly appreciate those who take the time to share their reactions to articles, particularly those who share releva ...

Core Viewpoint - The Organon class action lawsuit alleges that the company and its executives made misleading statements regarding capital allocation and dividend payouts, leading to significant financial losses for investors [1][4]. Group 1: Lawsuit Details - The lawsuit, titled Hauser v. Organon & Co., seeks to represent purchasers of Organon securities and claims violations of the Securities Exchange Act of 1934 [1]. - Allegations include the concealment of material information about Organon's capital allocation priorities and a drastic reduction of the quarterly dividend payout by over 70% [4]. - On May 1, 2025, Organon announced a reduction in its dividend payout from $0.28 to $0.02, resulting in a stock price drop of more than 27% [5]. Group 2: Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Organon securities during the class period to seek appointment as lead plaintiff [6]. - The lead plaintiff represents the interests of all class members and can select a law firm for litigation [6]. Group 3: Company Background - Organon develops health solutions through prescription therapies and medical devices [3]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized for securing substantial monetary relief for investors in securities fraud cases [7].

RA’ANANA, Israel, June 12, 2025 (GLOBE NEWSWIRE) -- RadView Software Ltd. (OTCMKTS:RDVWF) today announced that its Annual General Meeting of Shareholders will be held on July 23, 2025 at 15:00 PM (Israel time) at the offices of the Company, 4 Dolev Street, Raanana, 4366204, Israel The record date for the meeting is June 18, 2025. The agenda of the meeting is as follows: To re-elect Mr. Shai Beilis, Mr. Avi Fried, Mr. Ori Gal and Mr. Assaf Katan to the Company’s Board of Directors, to serve until the next an ...

Key Takeaways GE Vernova's gas turbine orders rose 11.8% year over year, lifting its equipment backlog to 29 GW. GEV's Gas Power revenues jumped 17.7% in Q1 2025, aided by rising AI and data center energy demand. GEV secured major 7HA turbine deals with Duke Energy and Chevron, boosting future power capacity.The growth of artificial intelligence (AI) and cloud computing has been significantly increasing electricity consumption of late, especially in hyperscale data centers worldwide. Surging electricity c ...

Regina, Saskatchewan--(Newsfile Corp. - June 12, 2025) - Above Food Ingredients Inc. (NASDAQ: ABVE) ("the Company"), is pleased to announce it has received the official compliance determination letter from NASDAQ confirming that the Company now meets full compliance and has satisfied all of the requirements under Listing Rules 5450(b)(3)(C), 5810(c)(3)(A) and 5450(a)(1).As referenced within our press release dated June 6, the Company regained compliance with listing Rule 5450(b)(3)(C), regarding the minimu ...

The T. Rowe Price Financials ETF, Health Care ETF and Natural Resources ETF began trading today and expanded the firm's ETF lineup to 22BALTIMORE, June 12, 2025 /PRNewswire/ -- T. Rowe Price (NASDAQ-GS: TROW), a global investment management firm, announced today the addition of three new active transparent equity exchange-traded funds (ETF): T. Rowe Price Financials ETF (Ticker: TFNS), T. Rowe Price Health Care ETF (Ticker: TMED), and T. Rowe Price Natural Resources ETF (Ticker: TURF). The new funds began t ...

Magnera’s Sontara® brand wins INDA’s® Long-Life Achievement Award at IDEA® 25 Magnera CEO, Curt Begle joins Product Line Management Director, Seth Good and Innovation Manager, Vinit Singh to celebrate the award win at IDEA® 25 CHARLOTTE, N.C., June 12, 2025 (GLOBE NEWSWIRE) -- Sontara®’s EcoRE bags, now part of the Magnera® portfolio, recently received the IDEA® Long-Life Achievement Award at IDEA 25, the premier global event for nonwovens and engineered fabrics. Made from cellulosic fibers, Sontara Eco ...

Key Takeaways CRWV stock soared 137% in a month, beating gains from MSFT, AMZN, and the broader tech sector. Surging AI demand led to a 420% jump in Q1 revenues, while the $11.9B OpenAI deal adds further upside. CRWV guides 2025 revenue at $4.9B-$5.1B, backed by increasing demand and a $259B revenue backlog.CoreWeave, Inc. (CRWV) stock has gained 136.6% in the past month and closed last session at $149.70, jumping more than threefold from its initial opening price of $39. It has outperformed the 5.4% grow ...

Key Takeaways PM's smoke-free products made up 44% of Q1 gross profit, led by IQOS and ZYN shipments. ZYN shipments soared 53% in Q1, with PM raising 2025 shipment guidance to 800-840 million cans. PM's smoke-free gross margin topped 70%, far exceeding combustibles, with products in 95 markets.Philip Morris International Inc. (PM) is accelerating its shift from traditional tobacco to reduced-risk products, with strong momentum in its flagship offerings — IQOS and ZYN. In the first quarter of 2025, smoke-f ...